132 related articles for article (PubMed ID: 38723626)
21. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Wang Q; Guo Y; Liu L; Schwanz LT; Li Z; Nair MS; Ho J; Zhang RM; Iketani S; Yu J; Huang Y; Qu Y; Valdez R; Lauring AS; Huang Y; Gordon A; Wang HH; Liu L; Ho DD
Nature; 2023 Dec; 624(7992):639-644. PubMed ID: 37871613
[TBL] [Abstract][Full Text] [Related]
22. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
Salleh MZ; Derrick JP; Deris ZZ
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299045
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
24. Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight.
Khan MI; Baig MH; Mondal T; Alorabi M; Sharma T; Dong JJ; Cho JY
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835101
[TBL] [Abstract][Full Text] [Related]
25. Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
Niu S; Zhao Z; Liu Z; Rong X; Chai Y; Bai B; Han P; Shang G; Ren J; Wang Y; Zhao X; Liu K; Tian W-x; Wang Q; Gao GF
J Virol; 2024 Mar; 98(3):e0115723. PubMed ID: 38305152
[TBL] [Abstract][Full Text] [Related]
26. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
[TBL] [Abstract][Full Text] [Related]
28. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.
McCallum M; Czudnochowski N; Rosen LE; Zepeda SK; Bowen JE; Walls AC; Hauser K; Joshi A; Stewart C; Dillen JR; Powell AE; Croll TI; Nix J; Virgin HW; Corti D; Snell G; Veesler D
Science; 2022 Feb; 375(6583):864-868. PubMed ID: 35076256
[TBL] [Abstract][Full Text] [Related]
29. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
Nabel KG; Clark SA; Shankar S; Pan J; Clark LE; Yang P; Coscia A; McKay LGA; Varnum HH; Brusic V; Tolan NV; Zhou G; Desjardins M; Turbett SE; Kanjilal S; Sherman AC; Dighe A; LaRocque RC; Ryan ET; Tylek C; Cohen-Solal JF; Darcy AT; Tavella D; Clabbers A; Fan Y; Griffiths A; Correia IR; Seagal J; Baden LR; Charles RC; Abraham J
Science; 2022 Jan; 375(6578):eabl6251. PubMed ID: 34855508
[TBL] [Abstract][Full Text] [Related]
30. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
31. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
[TBL] [Abstract][Full Text] [Related]
32. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
Park YJ; De Marco A; Starr TN; Liu Z; Pinto D; Walls AC; Zatta F; Zepeda SK; Bowen JE; Sprouse KR; Joshi A; Giurdanella M; Guarino B; Noack J; Abdelnabi R; Foo SC; Rosen LE; Lempp FA; Benigni F; Snell G; Neyts J; Whelan SPJ; Virgin HW; Bloom JD; Corti D; Pizzuto MS; Veesler D
Science; 2022 Jan; 375(6579):449-454. PubMed ID: 34990214
[TBL] [Abstract][Full Text] [Related]
33. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
[TBL] [Abstract][Full Text] [Related]
35. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Wang L; Zhou T; Zhang Y; Yang ES; Schramm CA; Shi W; Pegu A; Oloniniyi OK; Henry AR; Darko S; Narpala SR; Hatcher C; Martinez DR; Tsybovsky Y; Phung E; Abiona OM; Antia A; Cale EM; Chang LA; Choe M; Corbett KS; Davis RL; DiPiazza AT; Gordon IJ; Hait SH; Hermanus T; Kgagudi P; Laboune F; Leung K; Liu T; Mason RD; Nazzari AF; Novik L; O'Connell S; O'Dell S; Olia AS; Schmidt SD; Stephens T; Stringham CD; Talana CA; Teng IT; Wagner DA; Widge AT; Zhang B; Roederer M; Ledgerwood JE; Ruckwardt TJ; Gaudinski MR; Moore PL; Doria-Rose NA; Baric RS; Graham BS; McDermott AB; Douek DC; Kwong PD; Mascola JR; Sullivan NJ; Misasi J
Science; 2021 Aug; 373(6556):. PubMed ID: 34210892
[TBL] [Abstract][Full Text] [Related]
36. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.
Guo H; Ha S; Botten JW; Xu K; Zhang N; An Z; Strohl WR; Shiver JW; Fu TM
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793580
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the SARS-CoV-2 spike proteins affected the ACE2-binding affinity during the development of Omicron pandemic variants.
Tachibana K; Nakamura Y; Do TL; Kihara T; Kawada H; Yamamoto N; Ando K
Biochem Biophys Res Commun; 2024 Jul; 719():150120. PubMed ID: 38759524
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
